Bavarian Nordic A/S (BVNRY)
USD 7.57
(-0.66%)
USD 7.57
(-0.66%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.14 Billion DKK | 418.8% |
| 2022 | 395.4 Million DKK | 216.33% |
| 2021 | 85.94 Million DKK | -84.56% |
| 2020 | 819.12 Million DKK | 412.19% |
| 2019 | -269.21 Million DKK | 6.65% |
| 2018 | -300.46 Million DKK | -180.52% |
| 2017 | 387.63 Million DKK | 206.18% |
| 2016 | 91.97 Million DKK | -11.28% |
| 2015 | 127.68 Million DKK | 93.47% |
| 2014 | 115.58 Million DKK | 2.5% |
| 2013 | 58.91 Million DKK | 134.03% |
| 2012 | 15.68 Million DKK | 111.76% |
| 2011 | -234.23 Million DKK | 44.61% |
| 2010 | -420.16 Million DKK | -59.1% |
| 2009 | -273.23 Million DKK | -50.87% |
| 2008 | -175.04 Million DKK | -2029.28% |
| 2007 | -36.06 Million DKK | 95.55% |
| 2006 | -184.57 Million DKK | -117.89% |
| 2005 | -84.7 Million DKK | -2.9% |
| 2004 | -82.32 Million DKK | -138.46% |
| 2003 | 214.05 Million DKK | 1094.71% |
| 2002 | -21.51 Million DKK | 76.06% |
| 2001 | -89.88 Million DKK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 419.54 Million DKK | 1919.55% |
| 2024 Q1 | 58.56 Million DKK | -97.93% |
| 2023 FY | - DKK | 418.8% |
| 2023 Q4 | 1.06 Billion DKK | 181.0% |
| 2023 Q1 | 486.67 Million DKK | 39.17% |
| 2023 Q3 | 378.9 Million DKK | -45.88% |
| 2023 Q2 | 700.08 Million DKK | 43.85% |
| 2022 Q3 | 227.65 Million DKK | 448.71% |
| 2022 Q4 | 349.69 Million DKK | 53.61% |
| 2022 Q1 | -74.68 Million DKK | -245.46% |
| 2022 Q2 | -65.28 Million DKK | 12.59% |
| 2022 FY | - DKK | 216.33% |
| 2021 Q1 | 8.17 Million DKK | 103.54% |
| 2021 Q3 | 63 Million DKK | 2457.18% |
| 2021 FY | - DKK | -84.56% |
| 2021 Q4 | 51.34 Million DKK | -18.51% |
| 2021 Q2 | 2.46 Million DKK | -69.86% |
| 2020 Q2 | 221.13 Million DKK | -65.89% |
| 2020 Q1 | 648.35 Million DKK | 2950.93% |
| 2020 Q4 | -230.63 Million DKK | -243.0% |
| 2020 FY | - DKK | 412.19% |
| 2020 Q3 | 161.28 Million DKK | -27.06% |
| 2019 Q4 | -22.74 Million DKK | 69.07% |
| 2019 Q1 | -83.18 Million DKK | -10.99% |
| 2019 Q2 | -79.92 Million DKK | 3.92% |
| 2019 FY | - DKK | 6.65% |
| 2019 Q3 | -73.53 Million DKK | 7.99% |
| 2018 Q2 | -93.07 Million DKK | 42.1% |
| 2018 Q4 | -74.94 Million DKK | -247.29% |
| 2018 Q1 | -160.73 Million DKK | 6.54% |
| 2018 FY | - DKK | -180.52% |
| 2018 Q3 | 50.88 Million DKK | 154.67% |
| 2017 Q3 | 450.27 Million DKK | 557.21% |
| 2017 Q4 | -171.98 Million DKK | -138.19% |
| 2017 FY | - DKK | 206.18% |
| 2017 Q1 | -1.72 Million DKK | -101.06% |
| 2017 Q2 | 68.51 Million DKK | 4083.31% |
| 2016 Q1 | -160.44 Million DKK | -678.88% |
| 2016 Q2 | -27.63 Million DKK | 82.77% |
| 2016 FY | - DKK | -11.28% |
| 2016 Q3 | 138.1 Million DKK | 599.7% |
| 2016 Q4 | 162.67 Million DKK | 17.79% |
| 2015 FY | - DKK | 93.47% |
| 2015 Q4 | 27.71 Million DKK | 140.86% |
| 2015 Q3 | -67.83 Million DKK | -149.91% |
| 2015 Q2 | 135.9 Million DKK | 82.91% |
| 2015 Q1 | 74.3 Million DKK | -54.58% |
| 2014 Q3 | -8.6 Million DKK | 84.53% |
| 2014 Q4 | 163.58 Million DKK | 2002.1% |
| 2014 FY | - DKK | 2.5% |
| 2014 Q1 | 16.2 Million DKK | -41.76% |
| 2014 Q2 | -55.6 Million DKK | -443.21% |
| 2013 Q2 | 21.9 Million DKK | 178.21% |
| 2013 Q3 | 45.3 Million DKK | 106.85% |
| 2013 Q4 | 27.81 Million DKK | -38.6% |
| 2013 FY | - DKK | 134.03% |
| 2013 Q1 | -28 Million DKK | 44.57% |
| 2012 Q3 | 47.3 Million DKK | 56.62% |
| 2012 Q2 | 30.2 Million DKK | 306.85% |
| 2012 Q4 | -50.51 Million DKK | -206.8% |
| 2012 FY | - DKK | 111.76% |
| 2012 Q1 | -14.6 Million DKK | -127.26% |
| 2011 Q4 | 53.56 Million DKK | 281.57% |
| 2011 Q3 | -29.5 Million DKK | 75.68% |
| 2011 FY | - DKK | 44.61% |
| 2011 Q2 | -121.3 Million DKK | -14.76% |
| 2011 Q1 | -105.7 Million DKK | -4.18% |
| 2010 Q3 | -173.7 Million DKK | -432.82% |
| 2010 FY | - DKK | -59.1% |
| 2010 Q4 | -101.46 Million DKK | 41.59% |
| 2010 Q2 | -32.6 Million DKK | 65.68% |
| 2010 Q1 | -95 Million DKK | -67.87% |
| 2009 Q3 | -54.2 Million DKK | 34.78% |
| 2009 Q4 | -56.59 Million DKK | -4.42% |
| 2009 FY | - DKK | -50.87% |
| 2009 Q2 | -83.1 Million DKK | -32.75% |
| 2009 Q1 | -62.6 Million DKK | 0.0% |
| 2008 FY | - DKK | -2029.28% |
| 2007 FY | - DKK | 95.55% |
| 2006 FY | - DKK | -117.89% |
| 2005 FY | - DKK | -2.9% |
| 2004 FY | - DKK | -138.46% |
| 2003 FY | - DKK | 1094.71% |
| 2002 FY | - DKK | 76.06% |
| 2001 FY | - DKK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.74 Million USD | 122516.241% |
| Skye Bioscience, Inc. | -13.54 Million USD | 15913.066% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | -2178.1% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -406071.59% |
| Qrons Inc. | -40.08 Thousand USD | 5344984.11% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 28460.917% |
| CSL Limited | 4.78 Billion USD | 55.267% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 12433.235% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 55252.073% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 228744.569% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 3971.199% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 583477.04% |
| Rebus Holdings, Inc. | -951 Thousand USD | 225366.351% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 338851.214% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 13599.171% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 3115.771% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 36232.837% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 895890.508% |
| SQZ Biotechnologies Company | -64.14 Million USD | 3439.959% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 81110.593% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 139567.1% |
| Mesoblast Limited | -62.38 Million USD | 3533.71% |
| Marizyme, Inc. | -34.28 Million USD | 6349.099% |
| Genus plc | 73.7 Million USD | -2806.761% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 32502.291% |
| Pharming Group N.V. | 9.87 Million USD | -21589.612% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 144127.546% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 60497.074% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 24521.831% |
| ContraFect Corporation | -64.99 Million USD | 3395.871% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 47430.771% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 152922.854% |
| IMV Inc. | -35.52 Million USD | 6130.626% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 92287.992% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 413631.424% |
| ONE Bio Corp. | 13.61 Million USD | -15636.987% |
| Accustem Sciences Inc. | -3.74 Million USD | 57282.152% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 4542.082% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 169165.496% |
| Q BioMed Inc. | -617.62 Thousand USD | 346956.522% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -59874.328% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 93875.151% |
| Biomind Labs Inc. | -1.03 Million USD | 207174.097% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 5504.775% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 74167.826% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 30014.827% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -31860146.877% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 8569232.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 85724.122% |
| GB Sciences, Inc. | -1.41 Million USD | 150977.219% |
| Alpha Cognition Inc. | -9.7 Million USD | 22172.647% |
| HST Global, Inc. | -5303.00 USD | 40397667.415% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 104245.989% |
| Halberd Corporation | -74.27 Thousand USD | 2884203.179% |
| Enzolytics Inc. | -2.12 Million USD | 101054.464% |
| Agentix Corp. | -1.37 Million USD | 156270.85% |
| Resverlogix Corp. | -11.74 Million USD | 18344.618% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 70040.314% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -216.02 Million USD | 1091.692% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -175929.827% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -24096.196% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 143023.105% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -565378.931% |
| AVAX Technologies, Inc. | -6.11 Million USD | 35146.755% |
| Zenith Capital Corp. | -8.6 Million USD | 24992.9% |
| Genscript Biotech Corporation | -248.71 Million USD | 961.325% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 12297229.901% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 87666.612% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 1217137.801% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 111624.324% |
| Kadimastem Ltd | -2.62 Million USD | 81730.03% |
| Helix BioMedix, Inc. | -1.04 Million USD | 204846.099% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 1183106.605% |
| LadRx Corporation | 412.28 Thousand USD | -519514.682% |
| Cell Source, Inc. | -4.27 Million USD | 50240.9% |
| Regen BioPharma, Inc. | 1.46 Million USD | -146035.559% |
| NovAccess Global Inc. | -1.03 Million USD | 207124.47% |
| Affymax, Inc. | -14.29 Million USD | 15086.241% |
| Itoco Inc. | -1.86 Million USD | 114722.19% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 564423.007% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 192060.842% |
| Mobile Lads Corp. | -2.24 Million USD | 95688.176% |
| CytoDyn Inc. | -18.02 Million USD | 11982.428% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 2710855.545% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 17518155.442% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 441191.217% |
| SYBLEU INC | -141.57 Thousand USD | 1513321.634% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 201819.664% |
| International Stem Cell Corporation | 202 Thousand USD | -1060436.139% |
| Bioxytran, Inc. | -3.82 Million USD | 56178.549% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 4069786.55% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 87116.335% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 6072.519% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 4760728.889% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 78342.622% |
| Neutra Corp. | -181.24 Thousand USD | 1182068.805% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 10726.931% |
| PureTech Health plc | -11.62 Million USD | 18525.071% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 10727.659% |
| IXICO plc | -707 Thousand USD | 303110.325% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 27976.161% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 4531.148% |
| CSL Limited | 4.73 Billion USD | 54.737% |
| Cellectis S.A. | -92.63 Million USD | 2412.582% |